Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab window-of-opportunity in early breast cancer
NCT05180006Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in breast cancer, sponsored by Gustave Roussy. Primary endpoint: Change in GzmB+ CD8+ T cell levels at 14 days. Started Feb 2022; status: terminated.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05180006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180006.